Breaking News

AGC Biologics Delivers 1e11 TU of LVV Material in Nine Months

Expands its AGCellerate program to provide Lentiviral vector support for advanced therapies developers.

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced a Lentiviral vector (LVV) expansion to its AGCellerate program designed to deliver GMP material for clinical trials in an accelerated timeline. The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months. The AGCellerate LVV offering is supported by AGC Biologics’ proprietary ProntoLVV Platform, which offers a standardized pro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters